

PRESS RELEASE Stockholm July 13, 2023

ADDvise announces preliminary results for Q2 2023 that are stronger than expected

The preliminary results for ADDvise Group for the second quarter of 2023 significantly deviate from what ADDvise assesses as the market expectations.

SEK million	Q2 2023	Q2 2022	LTM June 2023
Net sales	342.7	231.9	1,206.0
Gross profit	232.9	139.9	768.0
Gross margin %	68.0%	60.3%	63.7%
EBITDA	121.0	34.3	333.7
EBITDA margin %	35.3%	14.8%	27.7%
EBITA	90.3	30.1	278.2
EBITA margin %	26.3%	13.0%	23.1%

The financial targets for the full year 2023, as previously communicated, are a pro forma EBITDA result of SEK 330 million and a pro forma net revenue of SEK 1.6 billion. Pro forma is calculated assuming that all acquisitions made during the current fiscal year are consolidated for the entire fiscal year. No new acquisitions have been consolidated in the second quarter of 2023.

The finance net in the second quarter will be negatively affected by one-time costs related to the refinancing of the previous bond in the amount of 37.1 MSEK.

The above-presented financial information is preliminary and will not be commented on by ADDvise Group until the report for the second quarter has been released.

ADDvise Group's report for the second quarter of 2023 will be published on July 20, 2023, at 07:45 am CEST.

ADDvise Group will hold an investor presentation at 1:00 pm CEST for investors and analysts. Please use the link below to participate:

<https://ir.financialhearings.com/addvise-group-q2-2023/register>

Important information

This information is information that ADDvise Group AB is required to disclose under the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out below, on July 13, 2023 at 08:00 am CEST.

For further information, please contact:

Rikard Akhtarzand, CEO

+46 765-25 90 71

rikard.akhtarzand@addvisigroup.se

About ADDvise Group

ADDvise Group AB (publ) is a leading supplier of equipment to healthcare and research facilities. The group consists of two business areas, Lab and Healthcare. Sales are global. The Group has a clear acquisition strategy with the aim of raising shareholder value and expand the business – both geographically and product wise. ADDvise Group's shares are listed on Nasdaq First North Premier and Mangold Fondkommission AB, +46 8 503 015 50, CA@mangold.se, is the Company's Certified Adviser. Additional information is available at www.addvisigroup.com.